The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Are The Forecasted Market Size Figures For The Neuralgia Treatment Market In 2026 And 2030?
The neuralgia treatment market has witnessed substantial growth in recent years. Projections indicate its value will escalate from $2.43 billion in 2025 to $2.58 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.1%. The market’s past expansion is attributable to several factors, including the rising prevalence of diabetic neuropathy cases, the early adoption of anticonvulsant medications, the increase in opioid-based pain treatment, greater awareness of neuralgia symptoms, and the expansion of hospital-based pain clinics.
The neuralgia treatment market is projected to experience substantial growth in the forthcoming years. It is anticipated to expand to $3.38 billion by 2030, at a compound annual growth rate (CAGR) of 7.0%. This growth during the forecast period is attributable to the increasing prevalence of minimally invasive surgical pain treatments, a rising demand for spinal cord stimulation devices, the growing application of targeted topical therapies, the expansion of telemedicine-based neuralgia care, and the development of next-generation non-opioid pain medications. Major trends expected in this period include the increased use of drug-based neuralgia management, a greater adoption of nerve block and decompression procedures, an escalating demand for topical pain relief therapies, the broadened application of spinal cord stimulation for chronic neuralgia, and an intensified focus on early diagnosis and long-term pain management.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12921&type=smp
What Key Growth Drivers Are Influencing The Neuralgia Treatment Market?
The increasing incidence of chronic illnesses, such as diabetes, is projected to fuel the future expansion of the neuralgia treatment market. Chronic diseases are conditions that persist for a year or longer, necessitating continuous medical attention, limiting daily activities, or both. Diabetes specifically refers to a long-term metabolic disorder marked by elevated levels of blood glucose, also known as blood sugar. Neuralgia treatment is capable of addressing diabetic neuropathy, which is the nerve damage that can affect individuals with diabetes. For example, in March 2024, data from the Office for Health Improvement and Disparities, a UK-based government department, indicated that between March 2022 and March 2023, the proportion of individuals with Type 1 diabetes who received all eight recommended care processes increased by 22%, and for Type 2 diabetes, this figure rose by 21%. Simultaneously, the percentage achieving target HbA1c levels climbed to 37.9%, which represents the highest value ever recorded by the National Diabetes Audit (NDA). Therefore, the growing prevalence of chronic diseases, particularly diabetes, is driving the growth of the neuralgia treatment market.
What Key Segment Areas Are Included In The Neuralgia Treatment Market Assessment?
The neuralgia treatment market covered in this report is segmented –
1) By Treatment: Drug-Based, Surgeries
2) By Indication: Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia
3) By Distribution channel: Drug Stores, Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
4) By End-User: Hospitals And Clinics, Ambulatory Surgery Centers, Other End-Users
Subsegments:
1) By Drug-Based: Anticonvulsants, Antidepressants, Opioids, Topical Treatments, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
2) By Surgeries: Nerve Block Procedures, Decompression Surgery, Neurectomy, Spinal Cord Stimulation
Which Trends Are Affecting The Neuralgia Treatment Market Framework?
Leading firms within the neural network software market are concentrating on creating innovative technology, including novel features like on-chip neural networks (NetGNT), designed for sophisticated traffic analysis. NetGNT denotes an artificial intelligence inference engine embedded directly onto a semiconductor chip, thereby facilitating machine learning functionalities. As an example, in November 2023, Broadcom Inc., a US-based semiconductor manufacturer, introduced Trident 5-X12, which stands as the inaugural switch featuring an on-chip neural network (NetGNT) intended for enhanced telemetry, security, and traffic engineering. This NetGNT system functions concurrently, detecting traffic patterns throughout the chip to improve overall network efficiency. The Trident 5-X12 provides a bandwidth of 16.0 Terabits/second, which is twice the capacity of Trident 4-X9, and is compatible with 800G ports for direct interfacing with Tomahawk 5. Furthermore, it consumes 25% less power per 400G port, incorporates improved telemetry features, and retains compatibility with existing APIs, positioning it as an adaptable and energy-efficient option for data centers.
Which Companies Are Influencing The Neuralgia Treatment Market?
Major companies operating in the neuralgia treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Biogen Inc., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Purdue Pharma, Dr. Reddy’s Laboratories, Cipla Limited, Hikma Pharmaceuticals plc, Zydus Lifesciences Ltd., Lupin Limited, Mallinckrodt Pharmaceuticals, Glenmark Pharmaceuticals
Access The Complete Neuralgia Treatment Market Report:
https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report
Which Region Leads The Neuralgia Treatment Market By Size?
North America was the largest region in the neuralgia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuralgia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Neuralgia Treatment Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=12921&type=smp
Browse Through More Reports Similar to the Global Neuralgia Treatment Market 2026, By The Business Research Company
Artificial Intelligence Ai Software Global Market Report 2026
Ai Toolkit Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/ai-toolkit-global-market-report
Generative Ai Software Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/generative-ai-software-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
